Osmosis sold unapproved drug products with disease claims and had dietary supplement CGMP and labeling violations.
What happened
FDA inspected Osmosis's Evergreen, CO facility from January 5, 2023, through January 13, 2023, and later reviewed product labels and the website. FDA found the products were intended as drugs because of claims to treat eczema, psoriasis, rosacea, diabetes, and high cholesterol, without drug approval or adequate directions. The inspection also found dietary supplement current good manufacturing practice (CGMP) violations and labeling violations.
What FDA found
The products were unapproved new drugs because they were intended to treat diseases such as eczema, psoriasis, rosacea, and diabetes.
section 201(p) and 505(a) of the Act [21 U.S.C. 321(p), 355(a)]The products lacked adequate directions for use because they were intended for diseases not suitable for self-treatment without a licensed practitioner.
section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]The firm had no written quality control procedures, including for material review and disposition decisions.
21 CFR 111.103The firm lacked written procedures and records for cleaning and sanitizing equipment, including the dust-removal equipment.
21 CFR 111.25(c), 111.27(d), and 111.35(a)The firm had no written procedures for reviewing and investigating product complaints.
21 CFR 111.553 and 111.560Several supplement labels lacked a domestic address or phone number for receiving serious adverse event reports.
section 403(y) of the Act [21 U.S.C. 343(y)]
What FDA wants
FDA asks Osmosis to notify it in writing within 15 working days of the specific steps taken to address the violations, including steps to prevent recurrence and copies of related documentation. If corrective actions cannot be completed in that time, FDA asks for the reason and the expected completion time.
Who should pay attention
- dietary supplement brands that make disease-type claims
- contract manufacturers and labelers of liquid supplements
- retailers and online platforms selling supplement products
This is a summary. Read the original letter on fda.gov.